Challenges and perspectives in the development of paper-based lateral flow assays

Kasetsirikul, Surasak; Shiddiky, Muhammad J. A.; Nguyen, Nam‐Trung

doi:10.1007/s10404-020-2321-z

Cited by 81 publications

(82 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The major advantage of LFAs is that they are easy to interpret as their results are typically Boolean and can be read out by the naked eye. However, LFAs lack accuracy and efficiency, which makes these conventional paper-based platforms not suitable for the more quantitative analysis which is desired in clinical applications ( Kasetsirikul et al, 2020 ). The ability of CRISPR/Cas complexes to discriminate between primer-dimers, non-target amplicons and amplicons of interest could make them the missing link in the current LFA field.…”

Section: Crispr/cas Sensing In Poc Sensorsmentioning

confidence: 99%

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Dongen

Berendsen

Steenbergen

et al. 2020

Biosensors and Bioelectronics

284

191

View full text Add to dashboard Cite

With the trend of moving molecular tests from clinical laboratories to on-site testing, there is a need for nucleic acid based diagnostic tools combining the sensitivity, specificity and flexibility of established diagnostics with the ease, cost effectiveness and speed of isothermal amplification and detection methods. A promising new nucleic acid detection method is Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated nuclease (Cas)-based sensing. In this method Cas effector proteins are used as highly specific sequence recognition elements that can be combined with many different read-out methods for on-site point-of-care testing. This review covers the technical aspects of integrating CRISPR/Cas technology in miniaturized sensors for analysis on-site. We start with a short introduction to CRISPR/Cas systems and the different effector proteins and continue with reviewing the recent developments of integrating CRISPR sensing in miniaturized sensors for point-of-care applications. Finally, we discuss the challenges of point-of-care CRISPR sensing and describe future research perspectives.

show abstract

Section: Crispr/cas Sensing In Poc Sensorsmentioning

confidence: 99%

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Dongen

Berendsen

Steenbergen

et al. 2020

Biosensors and Bioelectronics

284

191

View full text Add to dashboard Cite

show abstract

“…cocaine) and metabolites (e.g. ATP) 133 . However, despite huge market potential and popularity, the conventional LFA faces challenges such as batch-to-batch variation and instability 133 .…”

Section: Discussionmentioning

confidence: 99%

Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis

et al. 2021

View full text Add to dashboard Cite

Lateral flow assay (LFA) has made a paradigm shift in the in vitro diagnosis field due to its rapid turnaround time, ease of operation and exceptional affordability. Currently used LFAs predominantly use antibodies. However, the high inter-batch variations, error margin and storage requirements of the conventional antibody-based LFAs significantly impede its applications. The recent progress in aptamer technology provides an opportunity to combine the potential of aptamer and LFA towards building a promising platform for highly efficient point-of-care device development. Over the past decades, different forms of aptamer-based LFAs have been introduced for broad applications ranging from disease diagnosis, agricultural industry to environmental sciences, especially for the detection of antibody-inaccessible small molecules such as toxins and heavy metals. But commercial aptamer-based LFAs are still not used widely compared with antibodies. In this work, by analysing the key issues of aptamer-based LFA design, including immobilization strategies, signalling methods, and target capturing approaches, we provide a comprehensive overview about aptamer-based LFA design strategies to facilitate researchers to develop optimised aptamer-based LFAs.

show abstract

“…In a competitive lateral flow device, the analyte target will compete with the capture molecules immobilized on the test zone to bind to the specific molecule-conjugated-biolabels pre-stored on the conjugation pad. Thus, in the presence of the analyte target, the test line will not display the signal, while in the absence of the analyte target, there will be signals at both the test line and control line [421] , [423] . Thus, the target concentration is inversely proportional to the test line signal.…”

Section: Poc Devices For Infectious Disease Detectionmentioning

confidence: 99%

Point-of-care diagnostics for infectious diseases: From methods to devices

et al. 2021

View full text Add to dashboard Cite

show abstract

Challenges and perspectives in the development of paper-based lateral flow assays

Cited by 81 publications

References 143 publications

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis

Point-of-care diagnostics for infectious diseases: From methods to devices

Contact Info

Product

Resources

About